EUVIMEDEUVIMED entdecken
Crossref

MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy

Rushabh Gujarathi iD, Sara Abou Azar, Joseph Tobias, Blase N Polite, Namrata Setia, Nicholas Feinberg, Daniel E Appelbaum, Xavier M Keutgen, Chih-Yi Liao iD

Endocrine-Related Cancer · 2024

DOI: 10.1530/erc-24-0065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2024. Verfasst von Rushabh Gujarathi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Co-Repressor Proteins, Intestinal Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pre-clinical data suggest that mutations in the MEN1 , DAXX , and/or ATRX genes may potentially increase radiation efficacy in cancer cells. Herein, we explore the association between response to peptide receptor radionuclide therapy (PRRT) and those mutations in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). We analyzed tissue-based next generation sequencing (NGS) assay results and clinicopathologic data from 28 patients with GEP-NETs treated with PRRT. Findings were correlated with progression-free survival (PFS) and objective response rate (ORR). Patients with mutations in MEN1 , DAXX , and/or ATRX ( n = 13) had a longer median PFS (26.47 vs 12.13 months; P = 0.014) than wild-type ( n = 15) patients when adjusted for surgery prior to PRRT, tumor grade, and presence of TP53 mutation. Alterations in MEN1 along with a concurrent mutation in either DAXX or ATRX ( n = 6) trended toward longer PFS compared to patients without concurrent mutations (31.53 vs 17.97 months; P = 0.09). ORR was higher in patients with a mutation in MEN1 , DAXX , or ATRX (41.67% vs 15.38%). In pancreatic NET patients, these target mutations also showed a longer PFS (28.43 vs 9.83 months; P = 0.04). TP53 alterations showed a shorter PFS than wild-type cases (11.17 vs 20.47 months; P = 0.009). Mutations in MEN1 / DAXX / ATRX are associated with improved PFS in patients with GEP-NETs receiving PRRT and might be used as a biomarker for treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsCo-Repressor ProteinsIntestinal NeoplasmsMutationX-linked Nuclear ProteinStomach NeoplasmsMolecular ChaperonesProto-Oncogene ProteinsReceptors, PeptideHumansMaleFemaleMiddle AgedAgedAdultProgression-Free SurvivalAged, 80 and overOctreotide

Stichwörter der Autor:innen

ATRXDAXXMEN1PRRTgastroenteropancreatic NETpredictive biomarkers

Substanzen

Co-Repressor ProteinsDAXX protein, humanX-linked Nuclear ProteinMolecular ChaperonesATRX protein, humanProto-Oncogene ProteinsReceptors, PeptideMEN1 protein, humanOctreotide

Autor:innen und Institutionen

  • Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA.
  • Section of Endocrine Surgery, Department of Surgery, University of Chicago, Chicago, Illinois, USA.
  • Department of Pathology, University of Chicago, Chicago, Illinois, USA.
  • Department of Radiology, University of Chicago, Chicago, Illinois, USA.

ORCID-Profile: Rushabh Gujarathi, Chih-Yi Liao

Zitieren

APA

Gujarathi, R., Abou Azar, S., Tobias, J., Polite, B. N., Setia, N., Feinberg, N., Appelbaum, D. E., Keutgen, X. M., & Liao, C. Y. (2024). MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0065

Vancouver

Gujarathi R, Abou Azar S, Tobias J, Polite BN, Setia N, Feinberg N, et al. MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocrine-Related Cancer. 2024. doi:10.1530/erc-24-0065

BibTeX
@article{Gujarathi2024,
  author = {Gujarathi, Rushabh and Abou Azar, Sara and Tobias, Joseph and Polite, Blase N and Setia, Namrata and Feinberg, Nicholas and Appelbaum, Daniel E and Keutgen, Xavier M and Liao, Chih-Yi},
  title = {MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy},
  journal = {Endocrine-Related Cancer},
  year = {2024},
  doi = {10.1530/erc-24-0065}
}
Kostenlos starten →